Join three panelists who provide a practical overview of how and why to use data from Medicare for real world studies.
PHAR has conducted hundreds of studies using real world data (RWD) and has been using Medicare data for more than a decade. A specific research project is examined to highlight some important nuances in conducting these kinds of studies.
Key Topics Include:
- The main types of Medicare data available to researchers
- The process by which these data sets are obtained
- Strengths and weakness of Medicare data for conducting various types of RWD analysis
- Tricks and tips for completing your first study with Medicare data
Presenters
Vice President and Chief Statistician
Partnership for Health Analytic Research (PHAR)
Dr. Eunice Chang is a mathematician and statistician with 30 years’ experience in applying statistical analysis and design in a range of data types, including longitudinal surveys; commercial, Medicare, and Medicaid claims; and EHR. At PHAR, she leads many secondary data analyses and provides methodological and statistical support on others.
Principal Health Economist
Genentech, Inc.
Mitra Corral has been a Principal Health Economist at Genentech since 2018. She has extensive experience in HEOR having worked in Managed Care, Pharmaceutical, and Medical Device organizations. She earned her MS in Statistics from Rutgers University and an MPH in Epidemiology from University of Medicine & Dentistry of New Jersey.
President
Partnership for Health Analytic Research (PHAR)
Dr. Michael Broder has 30 years' experience in health economic and outcomes research. He has conducted dozens of expert panels on a wide variety of topics. In addition to being an experienced health services researcher, he is a board-certified physician and provides clinical expertise for many studies at PHAR.
Production Partner
PHAR
PHAR (Partnership for Health Analytic Research) brings together experienced methodologists and trained clinicians to produce high-quality real-world evidence that unlocks the hidden value of our clients’ innovative products.
Additional Content From PHAR
Achieving Consensus When Everyone is an Expert, but No One Agrees
Watch experts from PHAR, Novartis, and Bausch Health discuss the Delphi panels and how the results are used.
Cracking the Code: When and How to Validate ICD Algorithms for RWE
Experts from SickKids, Genentech, Penn Medicine, and PHAR deliver a high level overview on validation of code algorithms for Real World Evidence (RWE)
Additional Content From HealthEconomics.Com
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Watch a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
Related Content
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.
Economic Impact of Representativeness in Clinical Trials: How Real-World Data Can Help
This panel of real-world evidence (RWE) experts explore the economic impact and role of RWE in improving representativeness of research.